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Abstract
Background. Polyomavirus (PV) nephropathy may
coexist with or follow acute renal transplant rejection.
The aim of this study was to evaluate whether
HLA-DR and CD54 are useful cellular markers for
surveillance of acute rejection in PV-infected patients.
Methods. A prospective study was conducted using
205 renal transplant patients. Urine samples were
collected at a regular interval post-transplantation for
routine cytology and immunocytochemistry. Urinary
levels of tumour necrosis factor , soluble interleukin-2
receptor and interleukin-6 were used as adjunctive
markers for acute rejection.
Results. Of the 699 total samples, decoy cells were
identified in 100 samples of 50 patients. Patients with
decoy cell-positive (DCP) samples had higher serum
creatinine levels than decoy cell-negative (DCN)
samples (1.55 vs 1.41mg/dl, respectively; P¼ 0.006).
DCP samples were also more likely to be HLA-DR
positive (50.0 vs 32.4%; P¼ 0.029), as well as CD54
positive (17.4 vs 6.9%; P¼ 0.038). However, serum
creatinine levels did not correlate with HLA-DR or
CD54 positivity among DCP samples. Instead,
CD54 positivity correlated with decoy cell grades.
Immunosuppression decreased in 11 DCP patients,
and HLA-DR was negatively converted in three of
them. None of the patients developed acute clinical
rejection. Urinary cytokine levels did not correlate with
serum creatinine levels, nor did they correlate with
HLA-DR or CD54 status among DCP patients.
Conclusions. Urinary tubular HLA-DR and CD54
expression increased in decoy cell shedding patients but
did not indicate a concomitant acute rejection. These
markers may instead indicate renal inflammatory
activity associated with viral reactivation, which has
the potential to progress to PV interstitial nephritis.
Keywords: CD54; decoy cell; HLA-DR; polyomavirus;
pro-inflammatory cytokine; transplantation
Introduction
Polyomavirus (PV) nephropathy has emerged as a
major cause of acute graft dysfunction and failure.
Graft dysfunction is largely related to tubular necrosis
and interstitial nephritis [1,2]. However, the inflamma-
tion may be evoked or aggravated by acute graft
rejection either preceding or concomitantly with PV
interstitial nephritis [3,4]. Detecting acute rejection in
the setting of PV nephritis is important when
determining treatment strategies [5]. Renal biopsy can
be used as a diagnostic tool to confirm the diagnosis.
However, it is an invasive procedure, and it cannot
be repeated serially in patients suspected of having PV
nephritis.
Urine cytology has been successfully used as a
screening test for PV reactivation. It has also been used
for the diagnosis of acute rejection. Urinary decoy cells
correlate with renal tissue pathology. Likewise,
increased HLA-DR and CD54 expressions in detached
urinary epithelial cells [6–9] have been used to detect
acute rejection [8,10]. We could find only one promis-
ing report regarding the predictive value of increased
tubular HLA-DR expression in renal allograft biopsies
for concomitant acute rejection/PV nephropathy [4].
This study indicated that HLA-DR was a good
surrogate marker for the diagnosis of overlapping
acute rejection. However, there have been no further
reports supporting or disputing this notion. This
prospective study explores HLA-DR and CD54
expression in urinary epithelial cells in an attempt to
test the validity of immunohistochemistry in the
surveillance of acute rejection PV-infected renal
allograft patients. Urinary levels of tumour necrosis
factor  (TNF), soluble interleukin-2 receptor
(sIL-2R) and interleukin-6 (IL-6) were used as
adjunctive indicators for acute rejection.
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Subjects and methods
Patients
Patients enrolled in the study received renal allografts at
Yonsei University Medical Center, from January 2003 to
December 2004.
Urine and blood collection and renal biopsy
Morning urine was routinely collected at 1, 3, 6, 9 and
12 months post-transplantation on a regular basis.
In patients with urinary decoy cells or renal allograft
dysfunction, urine collection was repeated more frequently
and continued beyond the first year. Urine was centrifuged
at 1000 rpm for 5min. A cytospin smear was used
for Papanicolaou stain and immunocytochemistry. Urine
supernatant was divided into aliquots and kept at 708C
until use. Serum collection and measurement of creatinine
levels were performed on the same day as the urine collection.
The indication for renal biopsy is as follows: elevated
serum creatinine (0.3mg/dl or more above baseline),
proteinuria of greater than 1 g/24 h, and persistent
haematuria. No protocol biopsy was performed.
Urine cytology and decoy cell counting
A Papanicolaou stain was done using a cytospin smear. After
hydration with graded alcohol, the smears were stained with
Harris Haematoxylin for 3min. After washing with distilled
water, cells were quenched with 1% HCl for 30 s, washed and
then partially dehydrated. Cells were stained with Orange G6
for 2min, followed by an Eosin azure 50 stain for 2min.
After dehydration with graded alcohol, cells were cleared
with xylene. Decoy cells were counted and subdivided
into four grades: (1) Negative, no decoy cells; (2) Grade I,
1–3 decoy cells/10 high power field; (3) Grade II, 4–9 decoy
cells/10 high power field and (4) Grade III, 10 or more decoy
cells/10 high power field.
Immunocytochemistry
Cytospin-fixed cells were used for immunocytochemistry.
Cells were fixed for 10min in cold acetone, air-dried for
30min and then rehydrated in graded alcohol. After
treatment with 3% H2O2 for 20min in order to abolish
the endogenous peroxidase activity, the cells were placed in a
citrate buffer (pH 6.0), exposed to microwaves for 10min,
placed in a TRIS buffer (pH 7.6) for 10min and then
exposed to microwaves again for another 10min. After
blocking endogenous biotin, the cells were incubated
with primary antibodies against CD54 (DakoCytomation,
Glostrup, Denmark, in 1:200 dilution) and HLA-DR
(DakoCytomation, in 1:40 dilution) overnight at 48C.
They were then washed with a phosphate-buffered saline
buffer. Link antibodies and streptavidin-biotin peroxidase
was sequentially applied using the LSABR2 kit
(DakoCytomation). The reactions were coloured using
3,3-diaminobenzidine (DAB). The samples containing 50 or
more tubular cells per slide were evaluated. Positively stained
tubular epithelial cells were counted and expressed as
the percentage of total tubular cells.
Enzyme linked immunosorbent assay
Cytokine concentrations were measured using enzyme-linked
immunosorbent assay (ELISA). A 96-well plate was coated
with polyclonal rabbit antibody against TNF, sIL-2R and
IL-6 (Bender MedSystems GmbH, Campus Vienna Biocenter
2, Vienna, Austria). Examination was done in duplicate.
After thawing the urine samples at room temperature, 100l
of undiluted urine was added to each well. The same
amount of sample dilutent was added in the control wells.
After adding 50l of diluted biotin-conjugate in each well,
the plate was incubated for 2 h at room temperature. They
were then washed with wash buffer to remove unbound
biotin-conjugated cytokine. Next, 100l of Streptavidin-
HRP was added to each well. The plate was incubated
for 1 h at room temperature and then washed with
wash buffer. After adding 100l of tetramethyl benzidine
substrate solution, the plate was incubated for 10–20min
at room temperature. The reaction was stopped by
adding 100l of stop solution. The colour intensity was
measured using a spectrophotometer at 450 nm. Cytokine
concentrations in each sample were calculated using a
standard curve. Urinary cytokine levels were expressed
as urinary cytokine concentration:urine creatinine ratios to
standardize samples.
Serum and urine creatinine measurement
Using an automatic analyser (Hitachi 7600-210, Japan),
serum and urine creatinine levels were measured according to
the kinetic alkaline picrate method (Jaffe reaction).
Statistical analysis
Data were analysed using SPSS software, version 11.0
(Chicago, IL, USA). The Student t-test was applied to the
serum creatinine levels. A chi-square or Fisher’s exact test
was applied in order to test the relationship between urinary
HLA-DR and CD54 expression and decoy cell shedding.
One-way ANOVA with Scheffe’s post hoc test was used
to compare urinary cytokine secretion among decoy
cell shedding groups. Statistical significance was defined as
P-values <0.05.
Results
Urinary decoy cell shedding and correlation
with clinical findings
A total of 699 urine samples were collected from 205
patients. Urine samples were collected once from 39
patients, twice from 28 patients, three and four times
respectively from 2 groups of 33 patients each, five
times from 63 patients and more than five times from
nine patients. Urinary smear showed a mixture of
tubular cells, urothelial cells and inflammatory cells. It
was sometimes difficult or impossible to distinguish
between urothelial and tubular cells. Urothelial cells
are, however, generally larger than tubular cells, have
plump cytoplasm, and constitute a minor proportion in
decoy cell-positive (DCP) samples. Tubular cells were
readily identified mostly singly or rarely in small
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clusters in DCP samples, probably because viral
replication in tubular epithelial cells is often associated
with epithelial necrosis and acute tubular injury.
Nuclei of viral infected decoy cells showed character-
istic cytopathic changes with intranuclear inclusions
(Figure 1A); however, immunohistochemistry against
SV40 large T antigen demonstrated positive nuclear
staining in enlarged as well as normal appearing
tubular and urothelial cells.
Decoy cells were positive in 14.3% of the samples.
It was once in 33 patients, twice in 14, three times in 5,
four times in 7 and five times in 1 patient. The degree
of decoy cells fluctuated frequently from sample to
sample, even in the same patient. Of the 138 patients
who had performed urinalysis three times or more,
decoy cells were persistently negative in 96 (69.6%),
and decoy cells of grade III occurred two or more times
in seven patients (5.1%). The average serum creatinine
level was 1.43 mg/dl for all samples. Serum creatinine
levels were significantly higher in decoy-positive (DCP)
samples than in the samples without decoy cells
(P¼ 0.006); however, serum creatinine level did not
differ according to degrees of decoy cells (Table 1).
Immunosuppression was modulated in 11 patients,
secreting grade III decoy cells at least once, or grade II
at least twice. In six patients, the number of decoy
cells decreased within 6 months without significant
changes in serum creatinine level. In the remaining five
patients, follow-up data were not included since
immunomodulation occurred after the last urinalysis
during the study period. Clinical episodes of acute
rejection were observed in 34 patients in the first year
post-transplantation. Six of those 34 patients had
decoy cells that became positive after rescue therapy
(grade I in four patients, and grade III in two patients).
Correlation of urinary decoy cells with
renal biopsy findings
Renal biopsy was performed in only 18 of 205 patients
enrolled in this study. Excluding one unsatisfactory
sample, twenty-one renal biopsy samples were avail-
able for evaluation. Decoy cells were present in four of
the 18 patients, grades I and III in two patients each.
Two patients who secreted decoy cells of grade III at
the time of biopsy were diagnosed as PV nephropathy.
In two patients with grade I decoy cells, one patient
was diagnosed as IgA nephropathy and the other as
having mild tubular atrophy and interstitial fibrosis.
Of the remaining 14 decoy cell-negative (DCN)
patients, nine patients had acute rejection (five as
tubulointerstitial, four as vascular rejection). Decoy
cell shedding was not observed in any of the nine
patients before or after the diagnosis of acute rejection.
Two patients had chronic rejection. IgA nephropathy
and membranoproliferative glomerulonephritis was
diagnosed in one patient each. Biopsy findings were
non-specific in one patient.
Fig. 1. HLA-DR and CD54 immunoreactivity in a decoy cell-
positive case. Tubular nuclei are enlarged and show a ground glass
appearance [(A), Papanicolaou stain, 400]. Tubular cytoplasm of
infected cells is diffusely stained with both HLA-DR [(B), 400] and
CD54 antibodies [(C), 400].
Table 1. Urinary decoy cells and serum creatinine levels
Urinary
decoy cells
No. of patients No. of samples Serum creatinine
(mg/dl)
Negative 155 (75.6%) 599 (85.7%) 1.41a
Positive 50 (24.4%) 100 (14.3%) 1.55a
Grade I 34 (16.6%) 50 (7.2%) 1.56
Grade II 12 (5.9%) 16 (2.3%) 1.46
Grade III 26 (12.7%) 34 (4.9%) 1.58
Total 205 (100%) 699 (100%) 1.43
aP¼ 0.006.
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Urinary HLA-DR and CD54 expression and
its relationship to decoy cell shedding
Immunocytochemistry against HLA-DR and CD54
was done on 692 urine samples. Of these, 308 samples
contained at least 50 tubular cells per slide, with a
mean value of 110 cells (range 50–303) stained for
HLA-DR and 95 cells (range 50–523) stained for
CD54, and were the subject of the study (Figure 1B
and C). Forty-six samples contained decoy cells.
HLA-DR and/or CD54 were stained in tubular cells
as well as acute and chronic inflammatory cells. To
distinguish inflammatory cells positive for HLA-DR
and/or CD54 from tubular cells, staining against
cytokeratin antibody was performed using extra-
unstained smears having prepared in samples with a
sufficient amount of urine volume.
The percentages of HLA-DR-positive tubular cells
per slide were higher in DCP samples than DCN
samples (36.2 vs 25.6%), as were CD54-positive
tubular cells (12.4 vs 8.4%). However, only the latter
was statistically significant (P¼ 0.123 vs P¼ 0.008).
When the cut-off value was set at 30%, HLA-DR was
positive in 50% of DCP samples, which was higher
than the samples without decoy cells (32.4%,
P¼ 0.029). The same held true for CD54 positive
cells (17.4 vs 6.9%, P¼ 0.038). CD54-positive samples
were also HLA-DR-positive (Figure 1). HLA-DR
positivity did not differ according to decoy cell
grades, whereas CD54 positivity was significantly
different between grades I, II and III (P¼ 0.047)
(Table 2). When the DCP samples were divided
according to HLA-DR reactivity, the serum creatinine
levels of HLA-DR-positive samples (n¼ 22, 1.56mg/
dl) did not differ from the HLA-DR-negative samples
(n¼ 23, 1.67mg/dl). Two patients who were diagnosed
with PV nephropathy 2months prior to and at the time
of urinalysis, respectively, demonstrated HLA-DR and
CD54 positivities, along with increased serum creati-
nine levels (1.9 and 2.7mg/dl, respectively). Both pre-
and post-immunomodulation HLA-DR staining was
performed in five patients. Three patients who were
initially HLA-DR-positive showed negative conversion
with decreased immunosuppression, whereas two
HLA-DR-negative patients remained negative.
Six patients with acute rejection (three with the
tubulointerstitial type and three with the vascular type)
showed HLA-DR positivity of 83.3% and CD54 positi-
vity of 33.3% at the time of biopsy. The serum creatinine
level (2.43mg/dl) was significantly higher in these patients
as compared with the remaining patients (1.46mg/dl).
Urinary cytokine secretion and its relationship
to decoy cell shedding
Cytokine levels were tested in 85 DCP samples, 32
transplant urine samples without decoy cells and 10
samples from healthy controls. TNF and IL-6 levels
were higher in the transplant samples than in the
controls. However, there was no statistical difference.
The sIL-2R levels were lower in transplant samples
than in controls. This proved to be statistically
significant (Table 3). No relationship was observed
between urinary cytokine and serum creatinine levels.
Discussion
Several studies have demonstrated the usefulness of
HLA-DR and CD54 in the diagnosis of acute renal
allograft rejection [6–10]. HLA-DR has been reported
to be more sensitive, whereas CD54 has been reported
to be more specific. In the study, HLA-DR and CD54
expression was significantly increased in urinary
epithelial cells in patients with biopsy-confirmed
acute rejection (83.3 and 33.3%, respectively). This
confirms the usefulness of these two markers in
the detection of immune activation. Tubular
HLA-DR and CD54 expressions were 50 and 17.4%,
respectively, in DCP samples. This was also signifi-
cantly higher than that of DCN samples.
We speculated that increased HLA-DR and CD54
expression in DCP samples might be the result of
incorporating samples of patients with coexisting or
ongoing acute rejection. However, none of our data
Table 3. Urinary cytokine levels
Urinary cytokine level Healthy controls
(pg/mg)
Transplant P-value
Without decoy cell (pg/mg) With decoy cell (pg/mg)
TNF- 0.16 (n¼ 5) 2.84 (n¼ 8) 1.40 (n¼ 62) 0.055
IL-6/Ucr 0.01 (n¼ 10) 0.10 (n¼ 25) 0.07 (n¼ 78) 0.18
sIL-2R/Ucr 0.02 (n¼ 10) 0.01 (n¼ 20) 0.006 (n¼ 85) 0.001
*Ucr: urine creatine level.
Table 2. Urinary HLA-DR and CD54 expression according to
decoy cell excretion
Urinary
decoy cells
No. of
samples
No. of
HLA-DR-
positive
samples
No. of
CD54-positive
samples
Serum
creatinine
(mg/dl)
Negative 262 85 (32.4%)a 18 (6.9%)b 1.45
Positive 46 23 (50.0%)a 8 (17.4%)b 1.62
Grades I and II 23 10 (43.5%) 1 (4.3%)c 1.60
Grade III 23 13 (56.5%) 7 (30.4%)c 1.64
Total 308 108 (35.1%) 26 (64.9%) 1.48
aP¼ 0.029, bP¼ 0.038, cP¼ 0.047.
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supported this hypothesis. There were no differences in
serum creatinine levels or clinical features between
HLA-DR-positive and -negative samples at the time
of urinalysis. No patients with HLA-DR positivity
developed acute rejection, irrespective of decreased
immunosuppression. On the contrary, HLA-DR
negatively converted, with a decrease of decoy cells in
three DCP patients without significant changes in
follow-up serum creatinine levels. CD54-positive rates
correlated with decoy cell grades, but did not correlate
with serum creatinine level. Furthermore, urinary
HLA-DR and CD54 were increased at the time of
biopsy in two of the three patients with PV nephro-
pathy who also did not have histological features of a
coexisting acute rejection. Finally, urinary markers for
acute rejection such as TNF, sIL-2R and IL-6 [11]
were not helpful in distinguishing the two conditions.
Their levels were no different in samples with and
without decoy cells. These unexpected results made us
consider other conditions that might be responsible for
the increased immunoreactivities.
Conditions in which tubular HLA-DR and CD54
may be elevated include renal ischaemia [12–14],
urinary tract infection [15], obstructive uropathy [16],
aging [17] and tubulointerstitial nephritis [18]. These
diverse conditions have a common feature that they
may accompany interstitial inflammation [11,19].
It may also apply to PV nephritis since reactivation
of PV leads to decoy cell shedding in urine and
progresses to interstitial nephritis. A higher serum
creatinine level in patients with urinary decoy cells
compared with that in patients without decoy cells in
our study may indicate that an inflammatory response
was present in a substantial proportion of DCP
patients. Since the history of acute rejection episode
was a risk factor for PV replication, persistent
inflammation from a previous acute rejection may
also cause a temporary increase in the HLA-DR
expression in several patients. A recent report that
proinflammatory genes equal in character to that seen
in acute rejection can be transcribed in PV nephritis
[20] also supports our observation. Taken together,
increased HLA-DR and CD54 expressions in decoy
cell shedding patients may reveal renal inflammatory
activity, driven either via proinflammatory response
from the renal parenchyma to viral replication or as
a result of non-specific tubular damage and necrosis.
The major drawback of this study was the limited
number of biopsies. The lack of biopsies limited the
extent to which we could correlate to cytology samples.
Although urine cytology is helpful in the diagnosis
of acute cellular rejection, it cannot provide any
information about the presence of glomerulitis,
vasculitis or peritubular capillary C4d deposition,
which are crucial in the diagnosis of concurrent acute
rejection in PV nephropathy patients [5]. Inflammatory
response can be minimal to severe, both in acute
rejection and PV nephropathy according to the stages,
and 30–40% of PV nephropathy was concomitant with
acute rejection [21]. Therefore, the interpretation of
urinary immunocytology should be cautious without
biopsy findings or other supportive clinical findings
and PV replication data before exclusion of concurrent
acute rejection. Despite the limitations, our study
demonstrated that an increase in HLA-DR and CD54
expressions in patients secreting numerous decoy
cells may be at risk or already have some degree of
inflammation related to PV replication. In addition,
negative conversion of decoy cells with newly
developed HLA-DR positivity after immunomodula-
tion may raise a reasonable suspicion for ongoing
immune activation. These patients should therefore
undergo careful follow-up.
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